This clotting factor, which is the last factor that warfarin inhibits the synthesis of, has the longest half life.

This medication, which is the only injectable factor Xa inhibitor available in the US, should not be used for surgical prophylaxis in patients under 50 kg.

Patient is a 54 year old female weighing 47 kg. She has renal function and needs to be started on treatment dosing of Arixtra. This is her treatment dose.

This is a product of fibrin degradation and is used in diagnosis to rule out DVT or PE.

The understanding of many risk factors for vte can be associated with this model.

This is the VTE prophylaxis dose of heparin, that should be given to a 76 year old female that weighs 68 kg.

This medication is not indicated for VTE treatment.

Patient is on standard Xarelto dosing for VTE treatment. He is on day 4 and forgot to take his morning 15 mg dose and does not remember until it is time for his evening dose. The patient should…

This severe and sometimes fatal condition can occur later in a patient with DVT that breaks off.

A 53 year old male patient who weighs 73 kg is going to be started on Savaysa for Afib ppx. Patient has great renal function, with a CrCl of 110 mL/min. This is his ppx dose of Savaysa.

Pradaxa is ordered for a patient for DVT treatment. This must have received this prior.

A patient on SCD should be assessed for skin integrity and neurovascular status of the extremity every __ hours.

This is what UFH binds to in order to cause a conformational change that leads to the inactivation of Factors IIa and Xa.

This is the prophylactic dose and duration of Pradaxa in THA/TKA in patients with good renal function and no drug interactions.

A patient experiences their first unprovoked DVT and they have a low bleeding risk. This is the duration of treatment.

The CLOT trial determined that this drug had improved outcomes of preventing recurrent VTE in the setting of malignancy when compared to warfarin.

Both the intrinsic and extrinsic pathways lead to the activation of this clotting factor.

Patient is an 82 year old female, weighs 58 kg and SCr is 0.9. She is receiving Eliquis for Afib ppx. This is her dose.

Lovenox is ordered for a 54 year old female for an acute DVT. She is 71 kg, 165 cm tall, and has a SCr of 1.2. This is her VTE treatment dose.

This scoring system is for patients with afib to determine risk of stroke.